期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

DNA甲基化与多发性骨髓瘤 被引量：1

DNA Methylation and Mutiple Myeloma
下载PDF
导出
摘要 DNA甲基化是目前肿瘤领域研究中研究最多的表观遗传学机制之一.主要发生在DNA的CpG岛.DNA的甲基化通过甲基转移酶(DNA methyltransfeases,DNMTs)完成.DNA甲基化在多种肿瘤的发生、发展中都起到了重要的作用.大量研究发现,甲基化与多发性骨髓瘤的发生、发展及诊断治疗等有密切关系.深入探讨多发性骨髓瘤(MM)相关的甲基化可为MM发病机制的研究及治疗提供新的思路. DNA methylation is one of the most widely studied epigenetic events in tumor research. DNA methylation usually occurs at CpG island. DNA methylation is mediated by DNA methyltransfeases （DN- MTs）. DNA methylation plays an important role in the development and progression of lots of cancers. A great number of studies had indicated a strong correlation between the multiple myeloma （MM） and methyla- tion. Further studies on the MM associated methylation may provide new sights into MM pathogenesis and its diagnosis and treatment.
作者 张家铭 胡维新
机构地区 中南大学生物科学与技术学院
出处 《生命科学研究》 CAS CSCD 北大核心 2013年第3期278-282,共5页 Life Science Research
基金 国家自然科学基金资助项目(81071947) 中南大学研究生自主探索创新基金资助项目(2012zzts131)
关键词 甲基化 基因 多发性骨髓瘤(MM) methylation gene multiple myeloma（MM）
分类号 R733.3 [医药卫生—肿瘤]
  • 相关文献

参考文献37

  • 1JAIR K W,BACHMAN K E,SUZUKI H,et al.De novo CpGisland methylation in human cancer cells[J].Cancer Research,2006,66(2):682-692.
  • 2PAZ M F,FRAGA M F,AVILA S,et al.A systematic profileof DNA methylation in human cancer cell lines[J].Cancer Re-search,2003,63(5):1114-1121.
  • 3YOO K H,PARK Y K,CHANG S G,et al.DNA hypomethy-lation of interleukin 8 in clear cell renal cell carcinoma[J].Oncology Letter,2013,5(1):39-42.
  • 4OZDEMIR F,ALTINISIK J,KARATEKE A,et al.Methylationof tumor suppressor genes in ovarian cancer[J].Experimentaland Therapeutic Medicine,2012,4(6):1092-1096.
  • 5HIBI K,SAKUREBA K,SHIRAHATA A,et al.Methylation ofthe UNC5C gene is frequently detected in hepatocellular car-cinoma[J].Hepato-gastroenterology,2012,59(120):2573-2575.
  • 6HIBI K,SAKATA M,YOKOMIZI K,et al.Methylation of theWNT5A gene is frequently detected in early gastric carcinoma[J].Hepato-gastroenterology,2012,59(120):2661-2663.
  • 7HELLETR G,SCHMIDT W M,ZEGLER B,et al.Genome-wide transcriptional response to 5-aza-2′-deoxycytidine andtrichostatin a in multiple myeloma cells[J].Cancer Research,2008,68(1):44-54.
  • 8WALKER B A,WARDELLL C P,CHIECCHIO L,et al.Aberrant global methylation patterns affect the molecularpathogenesis and prognosis of multiple myeloma[J].Blood,2011,117(2):553-562.
  • 9HURT E M,THOMAS S B,PENG B J,et al.Reversal of p53epigenetic silencing in multiple myeloma permits apoptosis bya p53 activato[J].Cancer Biology&Therapy,2006,5(9):1154-1160.
  • 10HATZIMICHAEL E,DASOULA A,KOUNNIS V,et al.Bcl2-interacting killer CpG methylation in multiple myeloma:a po-tential predictor of relapsed/refractory disease with therapeuticimplications[J].Leukemia&Lymphoma,2012,53(9):1709-1713.

二级参考文献15

  • 1WANG Meng-chang,,FU Xue-de,LI Man-xiang.PI-3K/Akt/GSK-3p signaling cascades stimulated by insulin like growth factor-Ⅰcontribute to multiple myeloma cells proliferation and survival[J].Chinese Medical Journal,2006(14):1226-1229. 被引量：3
  • 2Kalushkova A, Fryknas M, Lemaire M, et al. Polycomb target genes are silenced in multiple myeloma. PLoS ONE ,2010 ;5 (7) : e11483.
  • 3Simon JA, Lange CA. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res,2008 ; 647( 1 -2) :21 -29.
  • 4Huang W, Zhu CL, Wang H, et al. The interferon consensus sequence-binding protein ( ICSBP/IRF8 ) represses PTPN13 gene transcription in differentiating myeloid cells. J Biol Chem, 2008; 283 (12) :7921 - 7935.
  • 5Yang D, Thangaraju M, Greeneltch K, et al. Repression of IFN regulatory factor 8 by DNA methylation is a molecular determinant of apoptotic resistance and metastatic phenotype in metastatic tumor ceils. Cancer Res,2007 ; 67 (7) : 3301 - 3309.
  • 6Tshuikina M, Jernberg-Wiklund H, Nilsson K, et al. Epigenetic silencing of the interferon regulatory factor ICSBP/IRF8 in human multiple myeloma. Exp Hematol, 2008 ;36(12) :1673 - 1681.
  • 7Sharma A, Heuck CJ, Fazzari MJ, et al. DNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancer. Wiley /nterdiscip Rev Syst Bio Med, 2010 ; 2 ( 6 ) : 654 - 669.
  • 8Croonquist PA, Van Ness B. The polycomb group protein enhancer of zeste homolog 2 (EZH2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype. Oncogene, 2005 ; 24(41 ) :6269 -6280.
  • 9McCabe MT, Brandes JC, Vertino PM. Cancer DNA methylation : molecular mechanisms and clinical implications. Clin Cancer Res, 2009 ; 5 ( 12 ) :3927 - 3937.
  • 10Peng B, Hurt EM, Hodge DR, et al. DNA hypermethylation and partial gene silencing of human thymine-DNA glycosylase in multiple myeloma cell lines. Epigenetics, 2006 ; 1 ( 3 ) : 138 - 145.

共引文献8

同被引文献2

引证文献1

生命科学研究
2013年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部